专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08377899B2 Composition for treatment of cervix cancer 有权
标题翻译：用于治疗子宫颈癌的组合物
公开(公告)号：US08377899B2
公开(公告)日：2013-02-19
申请号：US12513337
申请日：2007-11-05
申请人： Young Kee Shin , Hun Soon Jung , Yu Kyoung Oh
发明人： Young Kee Shin , Hun Soon Jung , Yu Kyoung Oh
IPC分类号： C12N15/113
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2320/31
摘要： The present invention relates to a composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papilloma virus (referred as “HPV” hereinafter) specific siRNA as an active ingredient and the second active part containing an anticancer agent as an active ingredient. The composition for the treatment of cancer of the present invention has better anticancer effect than the single therapy of the HPV specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration.
摘要翻译：本发明涉及用于治疗子宫颈癌的组合物，更确切地说，涉及用于宫颈癌治疗的组合物，其包含含有人乳头状瘤病毒（以下称为HPV）特异性siRNA作为有效成分的第一活性成分，第二活性部分含有抗癌剂作为活性成分。本发明的癌症治疗用组合物与HPV特异性siRNA或抗癌剂的单一疗法相比具有更好的抗癌作用，具有通过低浓度使用抗癌剂而降低副作用的优点。

2. 发明授权

US08425906B2 Method to inhibit cancer targeting CD24 有权
标题翻译：抑制癌症靶向CD24的方法
公开(公告)号：US08425906B2
公开(公告)日：2013-04-23
申请号：US12307108
申请日：2007-07-02
申请人： Young Kee Shin , Yoon-La Choi , Young Woo Park , Seung Hyun Lee , Kyoung Song
发明人： Young Kee Shin , Yoon-La Choi , Young Woo Park , Seung Hyun Lee , Kyoung Song
IPC分类号： A61K39/395
CPC分类号： A61K38/178 , A61K38/00 , A61K47/6803 , A61K47/6809 , A61K47/6813 , A61K47/6849 , A61K49/0008 , A61K51/1027 , A61K2039/505 , C07K16/2896 , C07K2317/732 , C07K2317/734 , C12N15/1138 , C12N2310/14 , A61K2300/00
摘要： The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.
摘要翻译：本发明涉及一种通过靶向CD24抑制癌症的方法，更确切地说，通过使用在大多数癌细胞中表达的CD24作为抗体治疗剂的靶标或通过抑制CD24和P-选择蛋白之间的相互作用来抑制癌症的方法。 CD24在大多数癌细胞中过度表达，并且在细胞质中累积的CD24加速转移。因此，通过靶向CD24抑制本发明的癌症的方法可以通过抑制过表达CD24的各种癌症的进展而有效地用于治疗癌症。

3. 发明申请

US20100062051A1 COMPOSITION FOR TREATMENT OF CERVIX CANCER 有权
标题翻译：用于治疗癌症的组合物
公开(公告)号：US20100062051A1
公开(公告)日：2010-03-11
申请号：US12513337
申请日：2007-11-05
申请人： Young Kee Shin , Hun Soon Jung , Yu Kyoung Oh
发明人： Young Kee Shin , Hun Soon Jung , Yu Kyoung Oh
IPC分类号： A61K9/127 , A61K31/7088 , A61K33/24
CPC分类号： C12N15/1131 , C12N2310/14 , C12N2320/31
摘要： The present invention relates to a composition for the treatment of cervix cancer, more precisely a composition for the treatment of cervix cancer comprising the first active part containing human papilloma virus (referred as “HPV” hereinafter) specific siRNA as an active ingredient and the second active part containing an anticancer agent as an active ingredient. The composition for the treatment of cancer of the present invention has better anticancer effect than the single therapy of the HPV specific siRNA or the anticancer agent, and has an advantage of reducing side effects by using the anticancer agent at a low concentration.
摘要翻译：本发明涉及用于治疗宫颈癌的组合物，更确切地说，涉及用于治疗子宫颈癌的组合物，其包含含有人乳头瘤病毒（以下称为“HPV”）特异性siRNA作为活性成分的第一活性成分，第二活性成分含有抗癌剂作为活性成分。本发明的癌症治疗用组合物与HPV特异性siRNA或抗癌剂的单一治疗相比具有更好的抗癌作用，具有通过低浓度使用抗癌剂而降低副作用的优点。

4. 发明申请

US20110300423A1 RECHARGEABLE BATTERY 有权
标题翻译：可充电电池
公开(公告)号：US20110300423A1
公开(公告)日：2011-12-08
申请号：US13017351
申请日：2011-01-31
申请人： Jae-Wook Lee , Young-Kee Shin , Yong-Sam Kim , Yong-Woo Kim
发明人： Jae-Wook Lee , Young-Kee Shin , Yong-Sam Kim , Yong-Woo Kim
IPC分类号： H01M2/02 , H01M10/36
CPC分类号： H01M2/0202 , H01M2/0217 , H01M2/0275 , H01M2/0277 , H01M2/0285 , H01M2/0287
摘要： A rechargeable battery prevents an electrolyte solution from being leaked from a can connector and improves the productivity of a can. A rechargeable battery constructed as an embodiment of the present invention includes an electrode assembly formed by stacking and winding a positive electrode, a separator, and a negative electrode; a can receiving the electrode assembly, and the can including a body formed by a polygonal tube and a bottom plate bent from at least one surface among multiple surfaces at an opening of the body and physically connected to the rest of the multiple surfaces of the body; and a cap assembly sealing another opening of the body and the cap assembly being disposed opposite to the bottom plate.
摘要翻译：可再充电电池防止电解质溶液从罐连接器泄漏并提高罐的生产率。作为本发明的实施方式构成的可再充电电池包括通过堆叠并卷绕正极，隔膜和负极而形成的电极组件; 容纳电极组件的罐体，并且罐体包括由多边形管形成的主体和从主体的开口处的多个表面中的至少一个表面弯曲的底板，并且物理连接到主体的多个表面的其余部分 ; 以及盖组件，其密封所述主体的另一开口，并且所述盖组件设置成与所述底板相对。

5. 发明授权

US09123916B2 Rechargeable battery 有权
标题翻译：可充电电池
公开(公告)号：US09123916B2
公开(公告)日：2015-09-01
申请号：US13017351
申请日：2011-01-31
申请人： Jae-Wook Lee , Young-Kee Shin , Yong-Sam Kim , Yong-Woo Kim
发明人： Jae-Wook Lee , Young-Kee Shin , Yong-Sam Kim , Yong-Woo Kim
IPC分类号： H01M2/02
CPC分类号： H01M2/0202 , H01M2/0217 , H01M2/0275 , H01M2/0277 , H01M2/0285 , H01M2/0287
摘要： A rechargeable battery prevents an electrolyte solution from being leaked from a can connector and improves the productivity of a can. A rechargeable battery constructed as an embodiment of the present invention includes an electrode assembly formed by stacking and winding a positive electrode, a separator, and a negative electrode; a can receiving the electrode assembly, and the can including a body formed by a polygonal tube and a bottom plate bent from at least one surface among multiple surfaces at an opening of the body and physically connected to the rest of the multiple surfaces of the body; and a cap assembly sealing another opening of the body and the cap assembly being disposed opposite to the bottom plate.
摘要翻译：可再充电电池防止电解质溶液从罐连接器泄漏并提高罐的生产率。作为本发明的实施方式构成的可再充电电池包括通过堆叠并卷绕正极，隔膜和负极而形成的电极组件; 容纳电极组件的罐体，并且罐体包括由多边形管形成的主体和从主体的开口处的多个表面中的至少一个表面弯曲的底板，并且物理连接到主体的多个表面的其余部分 ; 以及盖组件，其密封所述主体的另一开口，并且所述盖组件设置成与所述底板相对。

6. 发明授权

US08101716B2 Human interferon-beta mutein 有权
标题翻译：人类干扰素-β突变蛋白
公开(公告)号：US08101716B2
公开(公告)日：2012-01-24
申请号：US11718449
申请日：2005-11-02
申请人： Young Kee Shin , Moon Kyoung So , Jong Min Lee , Ji-Hye Yang , Ji Uk Yoo , Tae Ho Byun , Ji Tai Kim , Han Kyu Oh , Ho CHul Yoon , Ji Soo Ahn , Kyung Song , Jae Ho Jin
发明人： Young Kee Shin , Moon Kyoung So , Jong Min Lee , Ji-Hye Yang , Ji Uk Yoo , Tae Ho Byun , Ji Tai Kim , Han Kyu Oh , Ho CHul Yoon , Ji Soo Ahn , Kyung Song , Jae Ho Jin
IPC分类号： C07K14/00 , C07K14/52 , C12N15/00 , C12P21/04 , A61K38/21
CPC分类号： C07K14/565
摘要： The present invention relates to a human interferon-beta mutein. In particular, the present invention relates to the human interferon-beta mutein having one or two additional sugar chains compared to natural human interferon-beta.
摘要翻译：本发明涉及人类干扰素-β突变蛋白。特别地，本发明涉及与天然人类干扰素-β相比具有一个或两个另外的糖链的人类干扰素-β突变蛋白。

7. 发明申请

US20100166649A1 METHOD TO INHIBIT CANCER TARGETING CD24 有权
标题翻译：禁止癌症靶向CD24的方法
公开(公告)号：US20100166649A1
公开(公告)日：2010-07-01
申请号：US12307108
申请日：2007-07-02
申请人： Young Kee Shin
发明人： Young Kee Shin
IPC分类号： A61K51/00 , A61K39/395 , A61K38/19 , A61K38/20 , A61P35/00
CPC分类号： A61K38/178 , A61K38/00 , A61K47/6803 , A61K47/6809 , A61K47/6813 , A61K47/6849 , A61K49/0008 , A61K51/1027 , A61K2039/505 , C07K16/2896 , C07K2317/732 , C07K2317/734 , C12N15/1138 , C12N2310/14 , A61K2300/00
摘要： The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.
摘要翻译：本发明涉及一种通过靶向CD24抑制癌症的方法，更确切地说，通过使用在大多数癌细胞中表达的CD24作为抗体治疗剂的靶标或通过抑制CD24和P-选择蛋白之间的相互作用来抑制癌症的方法。 CD24在大多数癌细胞中过度表达，并且在细胞质中累积的CD24加速转移。因此，通过靶向CD24抑制本发明的癌症的方法可以通过抑制过表达CD24的各种癌症的进展而有效地用于治疗癌症。

8. 发明申请

US20100137149A1 DATA PROCESSING, ANALYSIS METHOD OF GENE EXPRESSION DATA TO IDENTIFY ENDOGENOUS REFERENCE GENES 审中-公开
标题翻译：数据处理，基因表达数据分析方法鉴定内源性参考基因
公开(公告)号：US20100137149A1
公开(公告)日：2010-06-03
申请号：US12521498
申请日：2007-12-27
申请人： Young Kee Shin , Mi Jeong Kwon , En Sel Oh , Yong Ho In , Sang Seok Koh
发明人： Young Kee Shin , Mi Jeong Kwon , En Sel Oh , Yong Ho In , Sang Seok Koh
IPC分类号： C40B30/02 , C40B40/08 , C12Q1/68 , G06F19/00
CPC分类号： G16B25/00 , C12Q1/6813 , C12Q1/6851 , C12Q2600/166 , C12Q2545/113 , C12Q2545/101
摘要： Disclosed are a data processing and analysis method of gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in the amplification of the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion’ and CV, the me allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Out of the 2,087 genes, 13 genes are found to show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTB, and therefore are suitable for the normalization of universal genes having relatively low expression levels.
摘要翻译：公开了用于鉴定内源参考基因的基因表达数据的数据处理和分析方法以及用于定量分析基因表达的组合物，其包含可用于扩增鉴定的内源性参考基因的一对引物和/或探针。引入了“零比例”和CV的概念，我允许不同的数据集被整体分析，从而寻找新的参考基因。通过该方法，首先发现2,087个基因作为在大多数组织中表达的管家基因，并且通过分析其表达稳定性来确定在不同靶基因的相对定量中的有用性。在2087个基因中，发现13个基因在传统参考基因如GAPDH和ACTB的范围内，具有较高的表达水平，具有较高的表达水平，因此适用于表达水平相对较低的通用基因的标准化。

9. 发明申请

US20100003721A1 HUMAN INTERFERON-BETA MUTEIN 有权
标题翻译：人间干扰素
公开(公告)号：US20100003721A1
公开(公告)日：2010-01-07
申请号：US11718449
申请日：2005-11-02
申请人： Young Kee Shin , Moon Kyoung So , Jong Min Lee , Ji-Hye Yang , Ji Uk Yoo , Tae Ho Byun , Ji Tai Kim , Han Kyu Oh , Ho Chul Yoon , Ji Soo Ahn , Kyung Song , Jae Ho Jin
发明人： Young Kee Shin , Moon Kyoung So , Jong Min Lee , Ji-Hye Yang , Ji Uk Yoo , Tae Ho Byun , Ji Tai Kim , Han Kyu Oh , Ho Chul Yoon , Ji Soo Ahn , Kyung Song , Jae Ho Jin
IPC分类号： C12P21/02 , C07K14/565 , C07H21/04 , C12N15/74 , C12N5/10
CPC分类号： C07K14/565
摘要： The present invention relates to a human interferon-beta mutein. In particular, the present invention relates to the human interferon-beta mutein having one or two additional sugar chains compared to natural human interferon-beta.
摘要翻译：本发明涉及人类干扰素-β突变蛋白。特别地，本发明涉及与天然人类干扰素-β相比具有一个或两个另外的糖链的人类干扰素-β突变蛋白。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式